Insider Buying: Eiger Biopharmaceuticals Inc (EIGR) Insider Purchases 1,000 Shares of Stock

Share on StockTwits

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) insider Stephana Eilene Patton acquired 1,000 shares of the firm’s stock in a transaction that occurred on Monday, April 22nd. The stock was acquired at an average price of $11.03 per share, for a total transaction of $11,030.00. Following the completion of the acquisition, the insider now directly owns 4,000 shares of the company’s stock, valued at approximately $44,120. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

EIGR traded down $0.06 during trading hours on Monday, reaching $10.97. The company’s stock had a trading volume of 388,100 shares, compared to its average volume of 109,151. Eiger Biopharmaceuticals Inc has a fifty-two week low of $8.20 and a fifty-two week high of $18.00. The stock has a market capitalization of $212.44 million, a PE ratio of -2.87 and a beta of 1.48. The company has a debt-to-equity ratio of 0.38, a quick ratio of 10.16 and a current ratio of 10.16.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last released its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.10). As a group, equities research analysts forecast that Eiger Biopharmaceuticals Inc will post -2.82 earnings per share for the current fiscal year.

Large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new position in Eiger Biopharmaceuticals during the fourth quarter worth $114,000. Wedbush Securities Inc. acquired a new position in Eiger Biopharmaceuticals during the first quarter worth $179,000. Dimensional Fund Advisors LP acquired a new position in Eiger Biopharmaceuticals during the third quarter worth $194,000. Millennium Management LLC acquired a new position in Eiger Biopharmaceuticals during the fourth quarter worth $255,000. Finally, Bank of America Corp DE lifted its stake in Eiger Biopharmaceuticals by 49.6% during the fourth quarter. Bank of America Corp DE now owns 25,884 shares of the biotechnology company’s stock worth $263,000 after purchasing an additional 8,581 shares in the last quarter. Institutional investors own 81.02% of the company’s stock.

A number of research analysts recently commented on EIGR shares. Wedbush reiterated a “buy” rating and issued a $43.00 price objective on shares of Eiger Biopharmaceuticals in a report on Tuesday, March 26th. BidaskClub upgraded Eiger Biopharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 22nd. ValuEngine upgraded Eiger Biopharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, February 4th. Finally, Robert W. Baird started coverage on Eiger Biopharmaceuticals in a report on Monday, January 28th. They issued an “outperform” rating and a $47.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $31.88.

WARNING: “Insider Buying: Eiger Biopharmaceuticals Inc (EIGR) Insider Purchases 1,000 Shares of Stock” was posted by Highlight Press and is the sole property of of Highlight Press. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://highlightpress.com/2019/04/22/insider-buying-eiger-biopharmaceuticals-inc-eigr-insider-purchases-1000-shares-of-stock.html.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

See Also: What is a Futures Contract?

Insider Buying and Selling by Quarter for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.